DVA

Business profile & competitive position

DaVita Inc. (DVA) sits in the Healthcare sector under the Medical - Care Facilities industry. Its core business is kidney dialysis and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company operated 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients, according to its most recent 10-K. The revenue base is heavily concentrated: U.S. dialysis represented roughly 86% of consolidated revenues, and the filing notes that nearly all non-hospital dialysis profits came from commercial payors.

That payor concentration is important for how investors read the margin profile. DaVita’s net margin is 6.0%—positive, but modest for a large-scale facility operator and consistent with a reimbursement-sensitive services business rather than a wide-moat, high-margin franchise. ROE is -123.6%, which looks alarming until it is viewed alongside positive reported earnings. A very negative ROE with positive net income typically signals a leveraged capital structure or negative book equity, often magnified by share buybacks, rather than a collapse in profitability. The market seems to look through that accounting effect: the stock trades at a P/E of 15.6, close to a market-average multiple, implying the market prices DaVita as a stable, cash-generative service provider despite the negative equity figure.

The company also has an international footprint of 585 outpatient dialysis centers across 14 countries serving approximately 94,500 patients, but that segment is materially smaller than the U.S. operation. Operational quality metrics have been strong: DaVita has been an industry leader in CMS’s Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years.

Financial posture

DaVita’s current financial snapshot includes a market cap of $11.7 billion, a P/E of 15.6, a net margin of 6.0%, a beta of 0.83, and an ROE of -123.6%. The sub-market beta of 0.83 fits a non-cyclical healthcare-services business; dialysis demand is not closely tied to the economic cycle. The 6.0% net margin highlights thin profitability—typical for a business whose revenue is shaped by government and commercial reimbursement schedules.

The standout figure is the -123.6% ROE. Because ROE equals net income divided by shareholder equity, a large negative value usually means equity is small or negative rather than that the business is losing money. Recent quarterly EPS has ranged from $2.51 to $4.02, confirming operating profitability. The dichotomy implies meaningful leverage or capital distribution. While the dataset does not include a debt figure, the combination of below-market beta, modest P/E, and deeply negative ROE points to a capital structure that deserves close inspection in the full financial statements.

Strategic priorities & outlook

DaVita’s most recent 10-K filing lays out three strategic priorities. The first is to reimagine high-quality kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The second is to build integrated care capabilities across the renal care continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. The third is to support the Comprehensive Kidney Care Contracting (CKCC) model’s goals of delaying disease progression, promoting home dialysis when clinically appropriate, and incentivizing transplants.

These priorities point to a business model that is trying to move upstream in the disease process and shift more treatment into the home setting. For a company that still derives 86% of revenue from U.S. dialysis, the success of CKCC participation and integrated care contracts is likely to influence both revenue mix and margin over the next several years.

Macro & geopolitical exposure

As a Medical - Care Facilities operator in the U.S. dialysis market, DaVita is exposed primarily to healthcare reimbursement policy and commercial insurance pricing rather than broad cyclical demand. Relevant macro-level factors include CMS fee schedules, Medicare Advantage penetration, and any federal or state rules on out-of-network billing and surprise medical billing. Because nearly all non-hospital dialysis profits come from commercial payors, shifts in commercial reimbursement rates or mix would likely have an outsized impact on earnings.

The 14-country international business adds currency risk and country-specific regulation. Operational factors common to care-facility operators—such as dialysis consumables supply chains, nurse and technician staffing, and wage inflation—are also relevant. Interest-rate risk is not a direct industry exposure, but given the leveraged appearance of the balance sheet, the cost of debt is a practical consideration.

Recent developments

Over the past several weeks, DVA has appeared repeatedly in Zacks headlines:

• 2026-09-09 — "Here's Why You Should Retain DaVita Stock in Your Portfolio for Now" (zacks.com)
• 2026-09-03 — "Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?" (zacks.com)
• 2026-09-03 — "Do Options Traders Know Something About DaVita Stock We Don't?" (zacks.com)
• 2026-08-28 — "4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds" (zacks.com)

The September 3 article flagged that DVA had drifted down 4.9% since its last earnings report. That is notable because the August 4 report was a beat, illustrating again that the headline result does not always drive sustained price action. The options-trading headline suggests market participants were positioning for larger implied volatility around upcoming events. The August 28 industry piece places DaVita among outpatient and home healthcare stocks, aligning with the CKCC and home-dialysis themes.

Earnings behavior & post-earnings drift

DaVita has beaten earnings estimates in six of the last eight quarters, a 75% beat rate, with an average surprise of +2.3%. The average five-day post-earnings move across those quarters was +6.36% (up). At first glance, that looks like a reliable pattern of beats and modest upward drift.

The last four quarters complicate the picture:

• 2026-08-04: actual EPS $4.02 vs. estimate $3.88 (+3.6% surprise, beat) — next-day move -17.24%, five-day move -21.78%
• 2026-05-05: actual EPS $2.87 vs. estimate $2.41 (+19.1% surprise, beat) — next-day move +23.46%, five-day move +27.7%
• 2026-02-02: actual EPS $3.40 vs. estimate $3.24 (+4.9% surprise, beat) — next-day move +21.17%, five-day move +23.79%
• 2025-10-29: actual EPS $2.51 vs. estimate $3.17 (-20.8% surprise, miss) — next-day move -6.17%, five-day move -4.27%

The August 2026 quarter is the clearest example of the disconnect: a 3.6% earnings beat was followed by a 17.24% single-day drop and a 21.78% five-day decline. That sequence undercuts the simple rule that a beat means the stock will pop and hold. Forward guidance, reimbursement concerns, or other qualitative factors can easily outweigh the reported EPS number.

The next scheduled report is October 28, 2026 after the market close. The market's real expectation, based on the unofficial consensus, is EPS of $3.58. Heading into that print, the stock is at $181.55, with an RSI of 42.7 and a 50-day EMA of $193.01—below its short-term moving average.

For a deeper dive into how analysts, institutions, and risk models currently view DaVita, readers should look at the full institutional verdict on the company.